Trump’s MFN policy is reshaping global pharma, not prices
From the original
https://think.ing.com/articles/mfn-keeps-expanding-while-the-benefit-for-american-patients-remains-unclear/
Related speeches
4 itemsTrump’s MFN policy is reshaping global pharma, not prices
The desk interprets the recent announcement of nine additional most-favored nation (MFN) deals as a strategic maneuver by the Trump Administration, which aims to reshape the pharmaceutical landscape rather than deliver significant price reductions for consumers. Per the full note [source], while these agreements extend MFN pricing to cover around 89% of the branded drug market, they are unlikely to lead to broad-based reductions in drug prices due to limitations on the scope and applicability of these pricing structures. Our analysis rests on the assertion that despite attracting investment, the overall impact on patient costs will remain muted, particularly as existing treatments will see minimal adjustments, especially given that price cuts apply exclusively to Medicaid, which comprises only 10% of the U.S. market. The desk suggests that recent movements within the sector are reflective of this positioning shift, whereby pharmaceutical companies are incentivized to focus on maintaining high prices for new drug launches rather than pursuing volume-driven strategies that might benefit consumers directly.
Where do we stand on pharmaceutical tariffs?
The desk's interpretation centers on the shifting landscape of pharmaceutical tariffs and its implications for global investment, particularly in the US. Per the full note [source], recent adjustments have introduced a layered tariff regime, which, while clarifying the overall picture, still leaves room for bilateral negotiations and potential reclassifications that could impact market dynamics. The significant investments by Swiss and European firms in the US pharmaceuticals, driven by preferential tariff treatment, highlight an emerging trend of ‘America First’ in the pharma landscape. This move could strengthen the dollar against the euro amid speculation surrounding future tariff measures.